MIRM — Mirum Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.61bn
- $5.92bn
- $521.31m
Mirum Pharmaceuticals 2025 sales rise
Brief: Mirum Pharmaceuticals Q4 Operating Expenses USD 153.499 Million
Brief: Mirum Pharma: Health Canada Authorizes Livmarli Tablet Formulation For Cholestatic Pruritus In Alagille Syndrome
Brief: Mirum Pharmaceuticals Says Health Canada Authorizes Livmarli For Cholestatic Pruritus In Progressive Familial Intrahepatic Cholestasis (Pfic) Patients
U.S. RESEARCH ROUNDUP-Cencora, Kennametal, Regeneron Pharmaceuticals
Brief: Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum
Brief: Mirum Pharmaceuticals Announces Additional Private Placement Financing With Tcgx
Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug (updated)
Deals of the day-Mergers and acquisitions
Brief: Mirum Pharmaceuticals To Acquire HBM Portfolio Company Bluejay Therapeutics
Brief: Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay Therapeutics
Mirum Pharma to buy Bluejay Therapeutics for up to $820 million
Brief: Mirum Enrolls First Patient in Phase 2 Fragile X Study of MRM-3379
Brief: Mirum Pharmaceuticals Receives Paragraph IV Notice From Sandoz On Livmarli - SEC Filing
U.S. RESEARCH ROUNDUP-ADM, Pinterest, Ul Solutions
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Brief: Mirum Pharmaceuticals Q3 EPS USD 0.05
U.S. RESEARCH ROUNDUP-Adobe, Nextdecade, United Airlines
Brief: Mirum Pharmaceuticals Announces Enrollment Completion In The Phase 2B Vistas Study